Simultaneous Estimation of Dapagliflozin and Teneligliptin Hydrobromide Hydrate in Synthetic Mixture by First Order Derivative
نویسندگان
1 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
2 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
3 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
4 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
5 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
6 Pharmaceutical Quality Assurance Department, B.K. Mody Government Pharmacy College, Rajkot , Gujrat, India
doi
10.48309/pcbr.2025.512283.1404چکیده
A straightforward, quick, accurate, and repeatable UV spectrophotometric simultaneous estimate technique for dapagliflozin and teneligliptin hydrobromide hydrate in a synthetic mixture was created and verified. First-order derivative spectroscopy is the foundation of the UV spectrophotometric approach. When water was used as a diluent, the absorbance of dapagliflozin and teneligliptin hydrobromide hydrate was measured at working wavelengths of 229 nm (the zero-crossing point of teneligliptin hydrobromide hydrate) and 215.8 nm (the zero-crossing point of dapagliflozin), respectively. According to the International Conference on Harmonisation (ICH), the created method's specificity, linearity, range, accuracy, precision, and robustness were validated. The linearity of the suggested method was examined for dapagliflozin in the range of 1-8 μg/ml (r2 = 0.9994) and for Teneligliptin hydrobromide hydrate in the range of 4-32 μg/ml (r2 = 0.9992). According to UV spectrophotometry, the percentage accuracy for dapagliflozin and teneligliptin hydrobromide hydrate was 99, 101.42, 100.1, and 100.9, respectively. The results showed that the devised approach is appropriate for routine analysis of the amount of teneligliptin hydrobromide hydrate and dapagliflozin in a synthetic mixture.
